Equity
€390,026 ▼ 0.2%
Gooreind Pharma paid out €60,000 in dividends. That is 101% of the 2025 profit.
Gooreind Pharma
Lifetime
20 annual accounts with figures on one time axis, 21 filings since 2005peak €487,006 (2025)
€487,006▲ 5.7%
lowest -€28,501 (2012)
€59,344▲ 3.9%
peak €473,514 (2022)
€390,026▼ 0.2%
€401,216▼ 17.9%
peak 4.6 FTE (2024)
4.4 FTE▼ 4.3%
Board3 names since 2017
2 directorsApotheek Dolhain and 1 other
Owners2 names in the annual accounts
35.42%KEMPEN PHARMA
Documentsfilings and deeds
04-08-20264 days late
2025abbreviated format
Dividend €60,000Debts from €488,892 to €401,216
Key points
from the 2025 annual accountsChecked score
93
Excellent
Financially stronger than 57% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,271 companies (NACE 47, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025lowest value
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.6%▲ +0.3 percentage points vs 07-2026highest value
09-2026: 0.1%▼ -0.5 percentage points vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Sector: Retail trade (NACE 47)
lowers risk
Founded in 2004
Liquidity: current ratio 2.37, cash €100,334
Equity €390,026 (49.3% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 64% of them on solvency, 61% on liquidity, 68% on profitability and 38% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 31,368 companies had the same profile as Gooreind Pharma has now. Each dot stands for 79 companies, two years later.
93.5%
were still trading
5.9%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of Gooreind Pharma itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for Gooreind Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €35,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.37 (2.09 in 2024), above the usual 1.5. Short-term debt is 27.3% and cash 12.7% of total assets. However, 50.7% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 04-08-2026, 4 days late. Weigh it accordingly: of the companies that move to filing 1 to 90 days late, 1.41% are now bankrupt, dissolved or in another special legal status, below the 1.66% of all filers. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
4 days late
2024
16 days early
2023
8 days early
2022
35 days early
2021
24 days early
2020
36 days early
2019
31 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 21 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- CATANT 64.58%equity €464,321 (2025) · 2025 annual accounts of CATANT
- KEMPEN PHARMA 35.42%equity €2.7m (2025) · 2025 annual accounts of KEMPEN PHARMA
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0870403170
Company renamed from Apotheek Jacques to Gooreind Pharma
Appointments: Apotheek Dolhain (director) and Kempen Pharma (director) · Permanent representatives: SLEEUBUS Inge and KEMPEN Ineke · “zoals opgenomen in artikel 4” (deed in Dutch) · General meeting of 16-11-2023 · Gazette deed
Resignation: Inge Sleeubus (director)
Permanent representative: Kristof Dolhain · Director discharge: Inge Sleeubus · General meeting of 31-12-2021 · Gazette deed
Incorporation
published on 17-12-2004 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Gooreind Pharma Wuustwezel | €791,241 | €487,006 | 49.3% | 4.4 |
| PHARMACIE CENTRALE DE MAURAGE La Louvière | €868,169 | €512,644 | 62.6% | 4.4 |
| GEASSOCIEERDE APOTHEEK PIOT Antwerp | €784,378 | €504,299 | 53.9% | 4.7 |
| APOBEL Zottegem | €683,671 | €463,587 | 72.3% | 4.5 |
| PHARMACIE TELLIER CONSEIL Woluwe-Saint-Lambert | €940,451 | €486,375 | 66.6% | 5.1 |
| PHARMACIE LAMBERT Liège | €830,901 | €422,965 | 58.1% | 5.3 |
| Apotheek Beekstraat Roeselare | €752,161 | €412,074 | 61.1% | 4 |
These companies have the same main activity as Gooreind Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €684,000 and €940,000, founded between 2000 and 2008.
Official details
Source: KBO- Status
- Active since 06-12-2004Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.144.063.3532990 Wuustwezel, since 29-11-2004
- Financial year end
- 31 December
- Peppol
- Reachable since 27-11-2025
Annual accounts 2025
- ≈ €1.7mestimated
- €791,241▼ 10.0%
- Employeeson 31-12-2025
- 7=
- Filing
- Filed on 04-08-2026
Insights on Gooreind Pharma
Gooreind Pharma files the abbreviated format. That format states no turnover. The gross margin rose from €127,977 in 2006 to €487,006 in 2025.
The balance sheet grew most from 2019 to 2021 through fixed assets.
CATANT holds 64.58% of the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Gooreind Pharma
- What is the company number of Gooreind Pharma?
- The company number of Gooreind Pharma is 0870.403.170. The VAT number is the same number with BE in front: BE 0870.403.170.
- Where is Gooreind Pharma based?
- The registered office is at Theo Verellenlaan 70, 2990 Wuustwezel.Company details
- What does Gooreind Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Gooreind Pharma?
- Gooreind Pharma is a private limited company (BV).
- When was Gooreind Pharma founded?
- Gooreind Pharma was founded on 06-12-2004.
- Is Gooreind Pharma still active?
- Yes, Gooreind Pharma is an active enterprise in the KBO register.
- How many employees does Gooreind Pharma have?
- Gooreind Pharma had an average of 4.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Gooreind Pharma fall under?
- In its 2025 annual accounts, Gooreind Pharma states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Gooreind Pharma?
- The turnover in financial year 2025 is ≈ €1.7m. This figure is estimated from the gross margin of €487,006 and 47 comparable companies (NACE 477). It probably lies between €1.3m and €2.7m.
- Is Gooreind Pharma profitable?
- In financial year 2025, Gooreind Pharma made a profit of €59,344.
- Where can I find the annual accounts of Gooreind Pharma?
- Gooreind Pharma filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Gooreind Pharma due?
- Gooreind Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.